A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
Latest Information Update: 19 Jan 2024
At a glance
- Drugs MGD 024 (Primary)
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myeloid leukaemia; Hairy cell leukaemia; Hodgkin's disease; Mastocytosis; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Sponsors MacroGenics
- 15 Mar 2023 According to Macrogenics media release, company continues enrollment in this study.
- 29 Aug 2022 Status changed from not yet recruiting to recruiting.
- 08 Aug 2022 According to a MacroGenics media release, first patient has been dosed in this trial.